Arena Pharmaceuticals’ Presence at United European Gastroenterology Week Strengthens Ongoing Commitment to the Gastrointestinal Disease Community
– New data from the Phase 2 OASIS trial and its open-label extension for etrasimod in ulcerative colitis – Arena